China NMPA approves Zai Lab’s TIVDAK for recurrent or metastatic Cervical cancer

CDSCO approves Trastuzumab deruxtecan plus Pertuzumab for first-line HER2-positive metastatic Breast cancer

China NMPA grants IND clearance to ADRX-0405 for advanced Solid tumors and Prostate cancer

Merck and Gilead discontinue phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy plus Keytruda in 1L metastatic...

AmMax Bio licenses antibody-drug conjugate technology for Hematological cancers from Lonza

Johnson & Johnson to acquire Firefly Bio to expand oncology pipeline with degrader ADC platform